News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point
      Drugs & Diseases

      paromomycin (Rx)

      Brand and Other Names:Humatin
      • Print

      Dosing & Uses

      AdultPediatric

      Dosage Forms & Strengths

      capsule

      • 250mg

      Intestinal Amebiasis (E. Histolytica)

      25-35 mg/kg/day PO divided q6hr for 5-10 days  

      Effective in acute and chronic but not extraintestinal

      Hepatic Coma (Adjunctive)

      4 g PO qDay in divided doses for 5-6 days

      Diantomoeba Fragilis

      20-30 mg/kg/day PO divided q8hr

      Tapeworm (T. saginata/T. solium/D. latum/D. caninum)

      11 mg/kg PO divided q15min for 4 doses

      Dwarf Tapeworm

      45 mg/kg/dose PO qDay for 5-7 days

      Cutaneous Leishmaniasis (Orphan)

      Treatment of cutaneous leishmaniasis (Old World and New World)

      Sponsor

      • The Surgeon General, Dept. of the Army; USAMRMC; 504 Scott Street; Ft. Detrick; MD

      Dosage Forms & Strengths

      capsule

      • 250mg

      E. Histolytica

      25-35 mg/kg/day divided q8hr PO for 7 days OR

      750 mg/m²/day divided q6hr PO for 5 days

      Dientamoeba Fragilis

      25-30 mg/kg/day PO divided q8hr for 7 days  

      Intestinal Amebiasis

      25-35 mg/kg/day PO divided q8hr for 5-10 days  

      Tapeworm (Hymenolepis nana)

      45 mg/kg PO qDay for 5-7 days  

      Tapeworm (T. saginata/T. solium/D. latum/D. caninum)

      11 mg/kg PO divided q15min for 4 doses  

      Dwarf Tapeworm

      45 mg/kg/dose PO qDay for 5-7 days

      Next:

      Interactions

      Interaction Checker

      and paromomycin

      No Results

         activity indicator 
        No Interactions Found
        Interactions Found

        Contraindicated

          Serious - Use Alternative

            Significant - Monitor Closely

              Minor

                All Interactions Sort By:
                 activity indicator 

                Contraindicated (0)

                  Serious - Use Alternative (21)

                  • atracurium

                    paromomycin increases effects of atracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea.

                  • axicabtagene ciloleucel

                    paromomycin, axicabtagene ciloleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

                  • BCG vaccine live

                    paromomycin decreases effects of BCG vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine.

                  • brexucabtagene autoleucel

                    paromomycin, brexucabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

                  • bumetanide

                    bumetanide, paromomycin. Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of ototoxicity and nephrotoxicity.

                  • ciltacabtagene autoleucel

                    paromomycin, ciltacabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

                  • cisatracurium

                    paromomycin increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea.

                  • ethacrynic acid

                    ethacrynic acid, paromomycin. Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of ototoxicity and nephrotoxicity.

                  • furosemide

                    furosemide, paromomycin. Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of ototoxicity and nephrotoxicity.

                  • idecabtagene vicleucel

                    paromomycin, idecabtagene vicleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

                  • lisocabtagene maraleucel

                    paromomycin, lisocabtagene maraleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

                  • onabotulinumtoxinA

                    paromomycin increases effects of onabotulinumtoxinA by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea.

                  • pancuronium

                    paromomycin increases effects of pancuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea.

                  • quinidine

                    quinidine will increase the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.

                  • rapacuronium

                    paromomycin increases effects of rapacuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea.

                  • rocuronium

                    paromomycin increases effects of rocuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea.

                  • succinylcholine

                    paromomycin increases effects of succinylcholine by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea.

                  • tisagenlecleucel

                    paromomycin, tisagenlecleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

                  • torsemide

                    torsemide, paromomycin. Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of ototoxicity and nephrotoxicity.

                  • typhoid vaccine live

                    paromomycin decreases effects of typhoid vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine.

                  • vecuronium

                    paromomycin increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea.

                  Monitor Closely (52)

                  • amikacin

                    amikacin and paromomycin both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

                  • amiodarone

                    amiodarone will increase the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • amphotericin B deoxycholate

                    amphotericin B deoxycholate and paromomycin both increase nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.

                  • bazedoxifene/conjugated estrogens

                    paromomycin will decrease the level or effect of bazedoxifene/conjugated estrogens by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.

                  • carboplatin

                    carboplatin and paromomycin both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

                  • cidofovir

                    cidofovir and paromomycin both increase nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.

                  • cisplatin

                    cisplatin and paromomycin both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

                  • clarithromycin

                    clarithromycin will increase the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • clotrimazole

                    clotrimazole will decrease the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • conjugated estrogens

                    paromomycin will decrease the level or effect of conjugated estrogens by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.

                  • contrast media (iodinated)

                    contrast media (iodinated) and paromomycin both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

                  • digoxin

                    paromomycin will increase the level or effect of digoxin by altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.

                  • dronedarone

                    dronedarone will increase the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • elvitegravir/cobicistat/emtricitabine/tenofovir DF

                    paromomycin and elvitegravir/cobicistat/emtricitabine/tenofovir DF both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

                  • erythromycin base

                    erythromycin base will increase the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • erythromycin ethylsuccinate

                    erythromycin ethylsuccinate will increase the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • erythromycin lactobionate

                    erythromycin lactobionate will increase the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • erythromycin stearate

                    erythromycin stearate will increase the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • estradiol

                    paromomycin will decrease the level or effect of estradiol by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.

                  • estrogens conjugated synthetic

                    paromomycin will decrease the level or effect of estrogens conjugated synthetic by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.

                  • estropipate

                    paromomycin will decrease the level or effect of estropipate by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.

                  • ethinylestradiol

                    paromomycin will decrease the level or effect of ethinylestradiol by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.

                  • felodipine

                    felodipine will increase the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • fosphenytoin

                    fosphenytoin will decrease the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • indinavir

                    indinavir will increase the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • ioversol

                    ioversol and paromomycin both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

                  • ketoconazole

                    ketoconazole will increase the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • lapatinib

                    lapatinib will increase the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • levoketoconazole

                    levoketoconazole will increase the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • levonorgestrel oral/ethinylestradiol/ferrous bisglycinate

                    paromomycin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy.

                  • loratadine

                    loratadine will increase the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • mestranol

                    paromomycin will decrease the level or effect of mestranol by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.

                  • methotrexate

                    paromomycin decreases levels of methotrexate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Paromomycin may decrease intestinal absorption of methotrexate or interfere with enterohepatic circulation by inhibiting bowel flora and suppressing metabolism of the drug by bacteria.

                  • nefazodone

                    nefazodone will increase the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • neomycin PO

                    neomycin PO and paromomycin both increase nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely.

                  • nicardipine

                    nicardipine will increase the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • nifedipine

                    nifedipine will decrease the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • oxaliplatin

                    oxaliplatin and paromomycin both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

                  • phenobarbital

                    phenobarbital will decrease the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • phenytoin

                    phenytoin will decrease the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • quercetin

                    quercetin will decrease the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • rifampin

                    rifampin will decrease the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • ritonavir

                    ritonavir will increase the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • sirolimus

                    sirolimus will increase the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • St John's Wort

                    St John's Wort will decrease the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • streptozocin

                    paromomycin and streptozocin both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

                  • tacrolimus

                    tacrolimus will increase the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                    paromomycin and tacrolimus both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

                  • teicoplanin

                    paromomycin and teicoplanin both increase nephrotoxicity and/or ototoxicity. Use Caution/Monitor.

                  • tobramycin inhaled

                    tobramycin inhaled and paromomycin both increase nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Avoid concurrent or sequential use to decrease risk for ototoxicity

                  • tolvaptan

                    tolvaptan will increase the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • trazodone

                    trazodone will decrease the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  • verapamil

                    verapamil will increase the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.

                  Minor (76)

                  • aceclofenac

                    aceclofenac increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • acemetacin

                    acemetacin increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • acyclovir

                    acyclovir and paromomycin both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

                  • adefovir

                    adefovir and paromomycin both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

                  • aspirin

                    aspirin increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • aspirin rectal

                    aspirin rectal increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • aspirin/citric acid/sodium bicarbonate

                    aspirin/citric acid/sodium bicarbonate increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • aztreonam

                    aztreonam, paromomycin. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Combination may be used synergistically against Pseudomonas spp. and Enterobacteriaceae.

                  • balsalazide

                    paromomycin will decrease the level or effect of balsalazide by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.

                  • biotin

                    paromomycin will decrease the level or effect of biotin by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.

                  • calcium acetate

                    paromomycin decreases levels of calcium acetate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                  • calcium carbonate

                    paromomycin decreases levels of calcium carbonate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                  • calcium chloride

                    paromomycin decreases levels of calcium chloride by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                  • calcium citrate

                    paromomycin decreases levels of calcium citrate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                  • calcium gluconate

                    paromomycin decreases levels of calcium gluconate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                  • capreomycin

                    capreomycin and paromomycin both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

                  • celecoxib

                    celecoxib increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • cephaloridine

                    cephaloridine and paromomycin both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

                  • choline magnesium trisalicylate

                    choline magnesium trisalicylate increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • clotrimazole

                    clotrimazole decreases levels of paromomycin by unknown mechanism. Minor/Significance Unknown.

                  • colistin

                    colistin and paromomycin both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

                  • cordyceps

                    cordyceps decreases toxicity of paromomycin by unspecified interaction mechanism. Minor/Significance Unknown.

                  • cyanocobalamin

                    paromomycin decreases levels of cyanocobalamin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                  • diclofenac

                    diclofenac increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • diflunisal

                    diflunisal increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • etodolac

                    etodolac increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • fenoprofen

                    fenoprofen increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • fluconazole

                    fluconazole decreases levels of paromomycin by unknown mechanism. Minor/Significance Unknown.

                  • flurbiprofen

                    flurbiprofen increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • foscarnet

                    foscarnet and paromomycin both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

                  • gentamicin

                    gentamicin and paromomycin both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

                  • ibuprofen

                    ibuprofen increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • ibuprofen IV

                    ibuprofen IV increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • indomethacin

                    indomethacin increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • ketoconazole

                    ketoconazole decreases levels of paromomycin by unknown mechanism. Minor/Significance Unknown.

                  • ketoprofen

                    ketoprofen increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • ketorolac

                    ketorolac increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • ketorolac intranasal

                    ketorolac intranasal increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • levoketoconazole

                    levoketoconazole decreases levels of paromomycin by unknown mechanism. Minor/Significance Unknown.

                  • lornoxicam

                    lornoxicam increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • magnesium chloride

                    paromomycin decreases levels of magnesium chloride by increasing renal clearance. Minor/Significance Unknown.

                  • magnesium citrate

                    paromomycin decreases levels of magnesium citrate by increasing renal clearance. Minor/Significance Unknown.

                  • magnesium hydroxide

                    paromomycin decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.

                  • magnesium oxide

                    paromomycin decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.

                  • magnesium sulfate

                    paromomycin decreases levels of magnesium sulfate by increasing renal clearance. Minor/Significance Unknown.

                  • meclizine

                    meclizine, paromomycin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Ototoxicity of aminoglycoside may be masked.

                  • meclofenamate

                    meclofenamate increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • mefenamic acid

                    mefenamic acid increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • meloxicam

                    meloxicam increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • methoxyflurane

                    methoxyflurane and paromomycin both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

                  • miconazole vaginal

                    miconazole vaginal decreases levels of paromomycin by unknown mechanism. Minor/Significance Unknown.

                  • nabumetone

                    nabumetone increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • naproxen

                    naproxen increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • oxaprozin

                    oxaprozin increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • pantothenic acid

                    paromomycin will decrease the level or effect of pantothenic acid by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.

                  • parecoxib

                    parecoxib increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • pentamidine

                    paromomycin and pentamidine both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

                  • piroxicam

                    piroxicam increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • polymyxin B

                    paromomycin and polymyxin B both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

                  • posaconazole

                    posaconazole decreases levels of paromomycin by unknown mechanism. Minor/Significance Unknown.

                  • pyridoxine

                    paromomycin will decrease the level or effect of pyridoxine by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.

                  • pyridoxine (Antidote)

                    paromomycin will decrease the level or effect of pyridoxine (Antidote) by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.

                  • salicylates (non-asa)

                    salicylates (non-asa) increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • salsalate

                    salsalate increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • streptomycin

                    paromomycin and streptomycin both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

                  • sulfasalazine

                    sulfasalazine increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • sulindac

                    sulindac increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • tenofovir DF

                    paromomycin and tenofovir DF both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

                    paromomycin increases levels of tenofovir DF by decreasing elimination. Minor/Significance Unknown.

                  • thiamine

                    paromomycin will decrease the level or effect of thiamine by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.

                  • ticarcillin

                    ticarcillin decreases effects of paromomycin by altering metabolism. Minor/Significance Unknown. Increased risk in renal impairment.

                  • tobramycin

                    paromomycin and tobramycin both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

                  • tolfenamic acid

                    tolfenamic acid increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • tolmetin

                    tolmetin increases levels of paromomycin by decreasing renal clearance. Minor/Significance Unknown. Interaction mainly occurs in preterm infants.

                  • vancomycin

                    paromomycin and vancomycin both increase nephrotoxicity and/or ototoxicity. Minor/Significance Unknown.

                  • voriconazole

                    voriconazole decreases levels of paromomycin by unknown mechanism. Minor/Significance Unknown.

                  • zoledronic acid

                    paromomycin, zoledronic acid. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive hypocalcemia.

                  Previous
                  Next:

                  Adverse Effects

                  1-10%

                  Diarrhea

                  Abdominal cramps

                  Nausea

                  Vomiting

                  Heartburn

                  <1%

                  Headache

                  Vertigo

                  Exanthema

                  Rash

                  Pruritus

                  Steatorrhea

                  Secondary enterocolitis

                  Eosinophilia

                  Ototoxicity

                  Previous
                  Next:

                  Warnings

                  Contraindications

                  Hypersensitivity, intestinal obstruction

                  Cautions

                  Prolonged treatment may result in fungal or bacterial superinfection

                  Caution in renal impairment or patients with ulcerative bowel lesions

                  Previous
                  Next:

                  Pregnancy & Lactation

                  Pregnancy Category: C

                  Lactation: does not enter breast milk

                  Pregnancy Categories

                  A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                  B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                  C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                  D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                  X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                  NA: Information not available.

                  Previous
                  Next:

                  Pharmacology

                  Mechanism of Action

                  Aminoglycoside; interferes with bacterial protein synthesis by binding to 30S ribosomal subunits; has antibacterial against pathogenic organisms in the GI tract

                  Pharmacokinetics

                  Absorption: Poor

                  Excretion: Feces (100% as unchanged drug)

                  Previous
                  Next:

                  Images

                  BRAND FORM. UNIT PRICE PILL IMAGE
                  Humatin oral
                  -
                  		250 mg capsule
                  paromomycin oral
                  -
                  		250 mg capsule
                  paromomycin oral
                  -
                  		250 mg capsule

                  Copyright © 2010 First DataBank, Inc.

                  Previous
                  Next:

                  Patient Handout

                  A Patient Handout is not currently available for this monograph.
                  Previous
                  Next:

                  Formulary

                  FormularyPatient Discounts

                  Adding plans allows you to compare formulary status to other drugs in the same class.

                  To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                  Create Your List of Plans

                  Adding plans allows you to:

                  • View the formulary and any restrictions for each plan.
                  • Manage and view all your plans together – even plans in different states.
                  • Compare formulary status to other drugs in the same class.
                  • Access your plan list on any device – mobile or desktop.

                  The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                  View explanations for tiers and restrictions
                  Tier Description
                  1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                  2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                  3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                  4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  NC NOT COVERED – Drugs that are not covered by the plan.
                  Code Definition
                  PA Prior Authorization
                  Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                  QL Quantity Limits
                  Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                  ST Step Therapy
                  Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                  OR Other Restrictions
                  Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                  CLOSE
                  Additional Offers
                  CLOSE
                  Email to Patient

                  From:

                  To:

                  The recipient will receive more details and instructions to access this offer.

                  By clicking send, you acknowledge that you have permission to email the recipient with this information.

                  CLOSE
                  Email Forms to Patient

                  From:

                  To:

                  The recipient will receive more details and instructions to access this offer.

                  By clicking send, you acknowledge that you have permission to email the recipient with this information.

                  Previous
                  Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
                  Find Us On
                  About
                  About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
                  Membership
                  Become a Member About You Professional Information Newsletters & Alerts Market Research
                  App
                  Medscape
                  WebMD Network
                  Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Medscape UK
                  Editions
                  English Deutsch Español Français Português UK
                  All material on this website is protected by copyright, Copyright © 1994-2023 by WebMD LLC. This website also contains material copyrighted by 3rd parties.